|
When in Doubt, Document: Identifying and Tackling Problems in CAPAs, NTFs
To minimize the risk of landing an FDA warning letter, clinical sites should carefully document even seemingly minor deviations, a site expert says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives